A. Laslop

发表

An Approach to Support the Performance Management of Public Health Authorities using an IT based Modeling Method

Dimitris Karagiannis, Hans-Georg Fill, Thomas Lang, 2011, Wirtschaftsinformatik.

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

A. Laslop, L. Makaroff, N. Wilking, 2019, ESMO Open.

Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice.

C C Glüer, J A Kanis, R Rizzoli, 2015, Bone.

Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary

F. Van de Werf, A. Laslop, G. Rosano, 2019, European heart journal. Acute cardiovascular care.

Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review

C. Cooper, J. Reginster, O. Bruyère, 2019, Calcified Tissue International.

Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.

J. Reginster, O. Bruyère, A. Laslop, 2005, Osteoarthritis and cartilage.

Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men

O. Johnell, J. Reginster, R. Rizzoli, 2005, Osteoporosis International.

Dense-core granules: a specific hallmark of the neuronal/neurosecretory cell phenotype

A. Laslop, J. Meldolesi, T. Giordano, 2004, Journal of Cell Science.

Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain.

J. Reginster, J. Kaufman, A. Laslop, 2003, Clinical and experimental rheumatology.

Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis

C. Cooper, J. Reginster, O. Bruyère, 2019, Advances in Therapy.

The Use of Placebo-Controlled and Non-inferiority Trials for the Evaluation of New Drugs in the Treatment of Postmenopausal Osteoporosis

J. Reginster, J. Kaufman, A. Laslop, 2002, Osteoporosis International.

Identification of two glycoproteins of chromaffin granules as the carboxypeptidase H

A. Laslop, R. Fischer‐Colbrie, H. Winkler, 1986, Neuroscience Letters.

Large Dense‐Core Vesicles in Rat Adrenal After Reserpine: Levels of mRNAs of Soluble and Membrane‐Bound: Constituents in Chromaffin and Ganglion Cells Indicate a Biosynthesis of Vesicles with Higher Secretory Quanta

N. Seidah, A. Laslop, S. Mahata, 1994, Journal of neurochemistry.

Biosynthesis of proteins of large dense-core vesicles in rat PC12 cells: Regulation by forskolin and phorbol ester

A. Laslop, C. Tschernitz, C. Eiter, 1994, Neuroscience.

Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ

L. Pani, A. Laslop, D. Melchiorri, 2014, Scientia pharmaceutica.

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis

C. Cooper, J. Reginster, O. Bruyère, 2015, Drugs & Aging.

Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment

J. Feldon, A. Laslop, W. Fleischhacker, 2001, Neuroscience.

Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.

J. Goldhahn, J. Reginster, R. Rizzoli, 2008, Bone.

α1-Antitrypsin Portland Inhibits Processing of Precursors Mediated by Proprotein Convertases Primarily within the Constitutive Secretory Pathway*

N. Seidah, A. Laslop, M. Marcinkiewicz, 1997, The Journal of Biological Chemistry.

Processing of secretogranin II by prohormone convertases: Importance ofPC1 in generation of secretoneurin

N. Seidah, A. Laslop, R. Fischer‐Colbrie, 1995, FEBS letters.

Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin

A. Laslop, R. Kirchmair, R. Fischer‐Colbrie, 1995, Progress in Neurobiology.

Immunological characterization of the endoproteases PC1 and PC2 in adrenal chromaffin granules and in the pituitary gland

A. Laslop, R. Kirchmair, R. Fischer‐Colbrie, 1992, FEBS letters.

Proteolytic processing of chromogranins.

A. Laslop, A. Doblinger, U. Weiss, 2000, Advances in experimental medicine and biology.

Nicotine and prostaglandin E induce secretogranin II levels in bovine chromaffin cells.

A. Laslop, R. Fischer‐Colbrie, M. Wolkersdorfer, 1996, Brain research. Molecular brain research.

Differences in the composition of chromaffin granules in adrenaline and noradrenaline containing cells of bovine adrenal medulla

A. Laslop, A. L. Cahill, R. Perlman, 1996, Neuroscience Letters.

Differential subcellular distribution of PC1, PC2 and furin in bovine adrenal medulla and secretion of PC1 and PC2 from this tissue

A. Laslop, R. Kirchmair, R. Fischer‐Colbrie, 1992, Neuroscience Letters.

Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach

M. Hiligsmann, O. Bruyère, A. Laslop, 2022, Aging Clinical and Experimental Research.

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.

N. Goel, J. Reginster, A. Laslop, 2011, Rheumatology.

Insulin hypoglycemia increases the levels of neuropeptide Y and calcitonin gene-related peptide, but not of chromogranins A and B, in rat chromaffin granules

A. Laslop, G. Sperk, C. Humpel, 1989, Regulatory Peptides.

Biosynthesis of large dense-core vesicles in PC12 cells: effects of depolarization and second messengers on the mRNA levels of their constituents.

A. Laslop, C. Tschernitz, H. Winkler, 1995, Brain research. Molecular brain research.

A. Laslop, K. Schmid, S. Mahata, 1992, Journal of neuroendocrinology.

Stimulation of rat adrenal medulla can induce differential changes in the peptide and mRNA levels of chromogranins, neuropeptides and other constituents of chromaffin granules

A. Laslop, C. Humpel, P. Fleming, 1991, Regulatory Peptides.

Divergent changes of chromogranin A/secretogranin II levels in differentiating human neuroblastoma cells

A. Laslop, E. Floor, S. Påhlman, 1990, FEBS letters.

The authors reply: Letter on: “Pitfalls in the measurement of muscle mass: a need for a reference standard” by Clark et al.

C. Cooper, J. Reginster, O. Bruyère, 2018, Journal of cachexia, sarcopenia and muscle.

Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients.

A. Laslop, R. Gasser, R. Fischer‐Colbrie, 2000, The Journal of clinical endocrinology and metabolism.

Neuropeptides and Chromogranins

A. Laslop, S. Mahata, 2002 .

Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach

M. Hiligsmann, O. Bruyère, A. Laslop, 2022, Aging Clinical and Experimental Research.

Secretoneurin in the peripheral ocular innervation.

A. Laslop, Johannes Leierer, K. Pfaller, 2005, Investigative ophthalmology & visual science.

Immunofluorescence for the Visualization of SN-Immunoreactive Nerves in Human and Rat Eye Tissues

A. Laslop, Johannes Leierer, K. Pfaller, 2005 .

Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)

C. Cooper, J. Reginster, R. Rizzoli, 2019, Ageing Research Reviews.

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

J. Reginster, R. Rizzoli, A. Laslop, 2008, Osteoporosis International.

Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.

J. Reginster, A. Laslop, P. Delmas, 2005, Seminars in arthritis and rheumatism.

Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia

C. Cooper, R. Rizzoli, J. Kanis, 2022, Nature Reviews Endocrinology.

Regulation of chromogranin biosynthesis by neurotrophic growth factors in neuroblastoma cells

A. Laslop, H. Winkler, C. Weiss, 2001, Neurochemistry International.

Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group

O. Bruyère, J. Kaufman, J. Kanis, 2022, Aging Clinical and Experimental Research.

Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations

M. D. de Wit, O. Bruyère, A. Laslop, 2022, Drugs.

Immunological characterization of a membrane glycoprotein of chromaffin granules: Its presence in endocrine and exocrine tissues

A. Laslop, R. Fischer‐Colbrie, H. Winkler, 1988, Neuroscience.

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

J. Reginster, R. Rizzoli, A. Laslop, 2008, Osteoporosis International.

Neurokinin a is a main constituent of sensory neurons innervating the anterior segment of the eye.

A. Laslop, C. Humpel, Johannes Leierer, 2005, Investigative ophthalmology & visual science.

Cellular distribution and molecular heterogeneity of MAC393 antigen (clusterin, beta-chain) on the surface membrane of bull spermatozoa.

A. Laslop, R. Jones, E. Howes, 1998, Molecular human reproduction.

Chromaffin granule membrane glycoprotein IV is identical with Ac45, a membrane-integral subunit of the granule's H+-ATPase

A. Laslop, H. Schägger, Jürgen Ludwig, 1996, Neuroscience Letters.

Lack of a distinctive behavioural effect of chromogranin-derived peptides in rodents

A. Laslop, G. Wakonigg, A. Saria, 2002, Regulatory Peptides.

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

J. Reginster, R. Rizzoli, D. Felsenberg, 2008, Bone.

Glycoprotein III (Clusterin, Sulfated Glycoprotein 2) in Endocrine, Nervous, and Other Tissues: Immunochemical Characterization, Subcellular Localization, and Regulation of Biosynthesis

A. Laslop, R. Fischer‐Colbrie, H. Winkler, 1993, Journal of neurochemistry.

Chromogranin A-processing proteinases in purified chromaffin granules: contaminants or endogenous enzymes?

A. Laslop, H. Kirschke, R. Fischer‐Colbrie, 1990, Biochimica et biophysica acta.

In Adrenal Medulla Synaptophysin (Protein p38) Is Present in Chromaffin Granules and in a Special Vesicle Population

A. Laslop, R. Fischer‐Colbrie, H. Winkler, 1988, Journal of neurochemistry.

Processing of chromogranins in chromaffin cell culture: effects of reserpine and alpha-methyl-p-tyrosine.

A. Laslop, C. Lazure, R. Fischer‐Colbrie, 1996, The Biochemical journal.

Quality of Life in Sarcopenia and Frailty

C. Cooper, J. Reginster, O. Bruyère, 2013, Calcified Tissue International.

Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

René Rizzoli, Nigel Arden, Mickaël Hiligsmann, 2013, Seminars in arthritis and rheumatism.

Effects of nerve growth factor on the biosynthesis of chromogranin A and B, secretogranin II and carboxypeptidase H in rat PC12 cells

A. Laslop, C. Tschernitz, 1992, Neuroscience.

Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?

C. Cooper, J. Reginster, R. Rizzoli, 2020, Osteoporosis International.

The new chromogranin-like protein NESP55 is preferentially localized in adrenaline-synthesizing cells of the bovine and rat adrenal medulla

A. Laslop, J. Marksteiner, R. Fischer‐Colbrie, 1999, Neuroscience Letters.

Assessing Medicines for Use in the Geriatric Population

A. Laslop, K. Vučić, F. Cerreta, 2022, Clinical pharmacology and therapeutics.

Neuroendocrine secretory protein 55: a novel marker for the constitutive secretory pathway.

A. Laslop, S. Eder, R. Fischer‐Colbrie, 2002, Annals of the New York Academy of Sciences.

Neuroendocrine Secretory Protein 55

A. Laslop, S. Eder, R. Fischer‐Colbrie, 2002, Definitions.

Management of Glucocorticoid-Induced Osteoporosis

C. Cooper, J. Reginster, R. Rizzoli, 2012, Calcified Tissue International.

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies

A. Barton, J. Reginster, A. Laslop, 2011, Annals of the rheumatic diseases.

Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016

A. Laslop, F. Breedveld, V. Annese, 2016 .

A. Laslop, 2013 .

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteo

C. Cooper, M. Hiligsmann, J. Reginster, 2019, Osteoporosis International.

Pitfalls in the measurement of muscle mass: a need for a reference standard

C. Cooper, J. Reginster, O. Bruyère, 2018, Journal of cachexia, sarcopenia and muscle.

Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review

C. Cooper, J. Reginster, O. Bruyère, 2019, Calcified Tissue International.

Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults

C. Cooper, J. Reginster, O. Bruyère, 2020, Aging Clinical and Experimental Research.

The Authors reply: “Dual energy X‐ray absorptiometry: gold standard for muscle mass?” by Scafoglieri et al.

C. Cooper, J. Reginster, O. Bruyère, 2018, Journal of cachexia, sarcopenia and muscle.

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty

C. Cooper, J. Reginster, O. Bruyère, 2015, Drugs & Aging.

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA

N. Goel, J. Reginster, A. Laslop, 2011, Current medical research and opinion.

Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

C. Cooper, J. Reginster, O. Bruyère, 2017, Seminars in arthritis and rheumatism.

Adherence to treatment of osteoporosis: a need for study

J. Reginster, V. Rabenda, R. Rizzoli, 2007, Osteoporosis International.

Antidepressant medications and osteoporosis.

C. Cooper, J. Reginster, V. Rabenda, 2012, Bone.

Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.

Jean-Pierre Devogelaer, Andrea Laslop, Jean-Yves Reginster, 2004, Osteoarthritis and cartilage.

Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties

O. Bruyère, M. Visser, A. Laslop, 2023, Aging Clinical and Experimental Research.

Erratum to: Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis

C. Cooper, J. Reginster, O. Bruyère, 2017, Drugs & Aging.

Proteolytic Processing of Chromogranin B and Secretogranin II by Prohormone Convertases

N. Seidah, A. Laslop, D. Savaria, 1998, Journal of neurochemistry.

Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

M. Hiligsmann, S. Silverman, O. Bruyère, 2023, Osteoporosis International.

Regulation of the biosynthesis and processing of chromogranins in organotypic slices: influence of depolarization, forskolin and differentiating factors

A. Laslop, A. Doblinger, R. Bauer, 2000, The European journal of neuroscience.

Seminars in Arthritis and Rheumatism

P. Tugwell, M. Hiligsmann, O. Bruyère, 2013 .

Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice.

J. Reginster, J. Kanis, A. Laslop, 2015 .

Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice.

J. Reginster, J. Kanis, A. Laslop, 2015, Bone.

Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO)

C. Cooper, J. Reginster, R. Rizzoli, 2019, Ageing Research Reviews.

Recommendations for the Registration of Agents Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

J. Reginster, J. Kaufman, A. Laslop, 1996, Calcified Tissue International.

Secretion and Molecular Forms of NESP55, a Novel Genomically Imprinted Neuroendocrine-Specific Protein from AtT-20 Cells

A. Laslop, Johannes Leierer, S. Eder, 2004, Neurosignals.